Simultaneous Imaging and Drug Delivery for Prostate Cancer Theranostics

前列腺癌治疗诊断的同步成像和药物输送

• 批准号: nhmrc : 1046831
• 负责人: A/Pr Kristofer Thurecht
• 金额: $ 37.69万
• 依托单位: Queensland University of Technology
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/simultaneous-imaging-drug-cancer-theranostics/111878
• 关键词: Simultaneous; Imaging; Drug; Delivery; Prostate

Prostate cancer (PC) is the most common cancer in men over 50. The answers to the key questions in advanced PC (Who to treat, and how to treat: loco-regionally or systemically?) rest with clinical staging – something that has hitherto been very imprecise. We have generated a highly-sensitive 19F-molecular imaging agent which could help resolve both questions and create a targeted therapy, diminishing the burden of harm of today’s therapies by using nanoparticles to diagnose and treat PC.

前列腺癌（PC）是50岁以上男性最常见的癌症。晚期前列腺癌的关键问题（治疗谁，以及如何治疗：局部区域还是系统？）的答案取决于临床分期——迄今为止，这是非常不精确的。我们已经研制出一种高灵敏度的19f分子显像剂，它可以帮助解决这两个问题，并创造一种靶向治疗方法，通过使用纳米颗粒来诊断和治疗PC，减少当今治疗方法的危害负担。